Phosphoproteomics reveals malaria parasite Protein Kinase G as a signalling hub regulating egress and invasion by Alam, Mahmood M. et al.
ARTICLE
Received 15 Aug 2014 | Accepted 26 Apr 2015 | Published 7 Jul 2015
Phosphoproteomics reveals malaria parasite
Protein Kinase G as a signalling hub regulating
egress and invasion
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Our understanding of the key phosphorylation-dependent signalling pathways in the human
malaria parasite, Plasmodium falciparum, remains rudimentary. Here we address this issue
for the essential cGMP-dependent protein kinase, PfPKG. By employing chemical and
genetic tools in combination with quantitative global phosphoproteomics, we identify the
phosphorylation sites on 69 proteins that are direct or indirect cellular targets for PfPKG.
These PfPKG targets include proteins involved in cell signalling, proteolysis, gene regulation,
protein export and ion and protein transport, indicating that cGMP/PfPKG acts as a signalling
hub that plays a central role in a number of core parasite processes. We also show that PfPKG
activity is required for parasite invasion. This correlates with the ﬁnding that the calcium-
dependent protein kinase, PfCDPK1, is phosphorylated by PfPKG, as are components of the
actomyosin complex, providing mechanistic insight into the essential role of PfPKG in parasite
egress and invasion.
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I
t is well established that protein phosphorylation is the
primary regulatory mechanism employed by eukaryotic cells
in the control of cellular processes1. This is clearly understood
in mammalian cells where many decades of research have
revealed the organization of the 4500 mammalian protein
kinases into phospho-signalling modules that are responsible for
generating the tens of thousands of cellular phosphorylation
sites2,3. These proteins are phosphorylated in a complex and often
highly dynamic manner, allowing for the precise co-ordination of
cellular events. Understanding the relationship between protein
kinases, the nature of phospho-signalling cascades and the
protein substrates associated with phospho-signalling modules
is central to acquiring a full appreciation of the mechanisms
that regulate cellular activity and to reveal important disease
mechanisms and potential therapeutic targets.
Whereas this area has been very fruitful in mammalian cell
biology, particularly when applied to the ﬁeld of cancer research4,
the understanding of phospho-signalling in malaria parasites is
still in its infancy5. Recently, published global phosphoproteomic
studies conducted on the most virulent species of human malaria
parasites, Plasmodium falciparum, have revealed that the 80–100
parasite protein kinases6–8 phosphorylate proteins involved in
nearly every aspect of the asexual blood stage of the parasite
life cycle9–12. Further, studies conducted largely on the
mouse malaria parasite, Plasmodium berghei, have revealed the
importance of protein phosphorylation in the mosquito stages13.
Hence, the essential role played by phosphorylation in the
development of both asexual and sexual stages of malaria
parasites, together with the high degree of phylogenetic distance
between the human and malaria protein kinases, supports the
notion that targeting parasite protein kinases would present
therapeutic opportunities not only for the treatment of malaria
but also in preventing onward transmission5.
One of the barriers to exploiting these opportunities is the
paucity of information regarding the role of essential protein
kinases and the nature of phospho-signalling cascades in
Plasmodium parasites11. Here, we address these issues by
combining chemical genetics and global phospho-proteomic
approaches to reveal the phosphorylation events mediated by
the P. falciparum guanosine 30,50-cyclic monophosphate (cGMP)-
dependent protein kinase, PfPKG (PF3D7_1436600). This protein
kinase is known to play an essential role not only in asexual blood
stages, where it is involved in both late stage schizogony14 and
egress of the parasite from red blood cells (RBCs)15,16, but also in
the mosquito stages, with demonstrated roles in gametogenesis17
and ookinete motility18,19 as well as late liver stage
development20. Importantly, the action of PfPKG is often
associated with calcium-dependent signalling. Thus, PfPKG has
been reported to act upstream of the calcium-dependent protein
kinase PfCDPK5 to regulate parasite egress16. Furthermore,
PfPKG is reported to be important in maintaining
elevated calcium levels, possibly through the regulation of
phosphoinositide biosynthesis, necessary for ookinete motility
in P. berghei and blood stage schizogony in P. falciparum18.
Our study aimed to provide an extensive evaluation of the
action of PfPKG in P. falciparum by employing a selective
inhibitor, termed Compound 2 (4-[7-[(dimethylamino)-
methyl]-2-(4-ﬂuorphenyl)imidazo[1,2-a]pyridine-3-yl] pyrimi-
din-2-amine)21, which acts by gaining access to a hydrophobic
pocket adjacent to the kinase ATP-binding pocket. The binding
of Compound 2 to PfPKG is thought to rely on the unusually
small, threonine, gate-keeper residue22. Binding of Compound
2 is blocked by the substitution of the threonine gate-keeper
with a bulkier glutamine residue. This mutant kinase termed
PfPKGT618Q, has previously been demonstrated to have a reduced
sensitivity for Compound 2 of 42,000-fold17. A mutant parasite
strain, where the wild-type Pfpkg allele was replaced by
PfPKGT618Q, has previously been used by us15,17,18, and the
equivalent in coccidian parasites has been used by others21, as a
chemical genetic tool to investigate the role of PKG in malaria
and other apicomplexans. Furthermore, preliminary studies from
our laboratories using metabolically ([32P]-orthophosphate)
labelled parasites indicated that PfPKG may have a number of
cellular substrates, although the identity and biological
signiﬁcance of these were not determined23.
Here we establish PfPKG-dependent phosphorylation events
in late P. falciparum blood stage schizonts by quantitatively
comparing the changes in global phosphorylation following
administration of Compound 2 to wild-type and PfPKGT618Q
mutant parasites. These studies revealed a number of novel
PfPKG-dependent phospho-proteins. Most notable were those
that have an involvement in parasite egress, invasion and calcium
signalling.
Results
Identity of PfPKG-dependent phosphorylation events. The
major challenge with using inhibitors of a speciﬁc protein kinase
is differentiating what are the on- and off-target actions of
the inhibitor. Here we use a genetically modiﬁed parasite
strain expressing the Compound 2-insensitive PfPKG mutant,
PfPKGT618Q, to deﬁne the on-target action of the inhibitor of
PfPKG, Compound 2. In these experiments, the targets for PfPKG
were identiﬁed by comparing the changes in the global phos-
phoproteome of wild-type late schizont stage parasites following
Compound 2 treatment (2 mM, 60min) with those changes
observed following Compound 2 treatment of the PfPKGT618Q
mutant parasite strain (Fig. 1). For a particular phosphorylation
event to be considered as being mediated by PfPKG (that is,
on-target action of Compound 2), that particular phospho-
peptide should be signiﬁcantly downregulated by Compound 2 in
wild-type parasites but not in PfPKGT618Q mutant parasites, in all
biological replicates (Fig. 1). In contrast, those phospho-peptides
that are downregulated equally by Compound 2 in wild-type and
mutant parasites are likely due to Compound 2 acting on a
protein kinase other than PfPKG and therefore considered as
off-target (for an example see Supplementary Fig. 1).
Here we conducted three independent experiments testing the
effects of Compound 2 on wild-type and PfPKGT618Q mutant
parasites. By applying the criteria described above, we established
that of the 2,931 unique phosphorylation sites identiﬁed in wild-
type schizonts (Supplementary Data 1) and 2,823 unique sites
in PfPKGT618Q mutant schizonts (Supplementary Data 2),
107 phosphorylation sites present on 69 phospho-proteins were
dependent on PfPKG activity and therefore can be considered as
cellular targets for PfPKG (Fig. 2 and Supplementary Data 3). The
mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository
with the dataset identiﬁer PXD002266 and 10.6019/PXD002266.
PfPKG cellular targets. Among the cellular targets for PfPKG are
proteins involved in cell signalling, proteolysis, ion transport,
transcriptional regulation, protein export and chromatin regula-
tion (Fig. 2). These phosphorylation events are in addition to the
PfPKG-dependent phosphorylation of 23 uncharacterized pro-
teins (Fig. 2), indicating the potential for PfPKG to play a wide-
ranging role in the regulation of numerous blood stage processes
(Fig. 2), similar to the extended role described for PKG isoforms
in mammalian cellular activity24. These varied cellular PfPKG-
targets correspond to the broad subcellular distribution of PfPKG
where the kinase was found at both membrane and cytoplasmic
sites as well as associated with the endoplasmic reticulum23.
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We addressed the question of how many of the 107 PfPKG-
dependent phosphorylation sites might be direct substrates for
PfPKG by assessing the number of sites that conformed to
the established PKG consensus motif (K/RR/KxpS/pT)24. In
addition, we considered the possibility that PfPKG might also
phosphorylate at the cAMP-dependent protein kinase (PKA)
consensus site K/RxxpS/pT9. This is based on studies, using
peptides and cellular protein substrates, that have reported
extensive overlap in the primary amino-acid sequences
phosphorylated by PKA and PKG25–27. Supplementary Data 4
shows that 46 of the 107 PfPKG-dependent phosphorylation sites
identiﬁed here conformed to one or other of these potential PKG
consensus motifs, raising the possibility that these sites are
directly phosphorylated by PfPKG. It is, however, not uncommon
for protein kinases to phosphorylate sites that do not conform
to consensus sequences. Thus, the number of sites actually
phosphorylated by PfPKG may be higher, or indeed lower, than
this estimate. What is certain is that our study demonstrates that
PfPKG can regulate the phosphorylation status of 69 parasite
proteins either directly or indirectly via the regulation of other
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Figure 1 | A schematic representation of the quantitative global phosphoproteomic study to determine the cellular targets for PfPKG. (a) Late schizont
stage parasites were puriﬁed on MACS column and incubated with or without Compound 2 (2mM, 60min) after which parasite lysates were prepared and
digested with trypsin. Peptide samples from individual experiments were labelled with isobaric mass tags and the peptides from three independent
experiments were pooled, then phosphopeptides were enriched by sequential fractionation using anion-exchange, PHOS-select (IMAC) and TiO2 beads
before being analysed by LC-MS/MS. (b,c) Illustrative mass spectra showing an example of a phosphopeptide that was less abundant following Compound
2 treatment (b) and one that was unchanged by Compound 2 treatment (c).
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protein kinases, and in this way, impact on a number of parasite
systems.
One such system appears to be a potential cyclic nucleotide
feed-back loop. This is indicated by the fact that one of the
four 30,50-cyclic nucleotide phosphodiesterases (PDEb: PF3D7_
1321500.2) and one of the two guanylyl cyclases (GCa:
PF3D7_1138400) were phosphorylated in a PfPKG-dependent
manner, indicative of feed-back mechanisms operating in cGMP
signalling, whereby both synthesis and degradation of cGMP
might be regulated by PfPKG. Furthermore, cross-talk between
cGMP and cAMP signalling was indicated by PfPKG-dependent
phosphorylation of adenylyl cyclase (ACb: PF3D7_0802600)
on S1572 (Fig. 2). These phosphorylation events point to the
possibility that cyclic nucleotide signalling in malaria parasites
show complex feed-back regulation similar to mechanisms in
operation in mammalian cells where PKA- and PKG-mediated
phosphorylation can regulate the activity of both cyclases and
phosphodiesterases24.
A number of proteins involved in transcription, translation and
chromatin dynamics were phosphorylated in a PfPKG-dependent
manner, indicating that cGMP signalling might play a role in
the regulation of gene expression across different levels in
Plasmodium schizonts (Fig. 2), either through direct PfPKG
activity or through down-stream PfPKG-regulated kinases (or
phosphatases). These phosphorylation events included a number
of sites on histones. One particular set of sites serine-29 (S29) and
serine-33 (S33) on histone 3 (H3.1: PF3D7_0610400) contained
within the peptide KSAPISAGIK (underlined/bold residues
indicate the phosphorylation sites) were phosphorylated in a
PfPKG-dependent manner, as were the equivalent sites on
the histone 3 variant (H3.3: PF3D7_0617900; KSAPVSTGIK).
Histone-H3.1 S29 phosphorylation (H3S29) is a conserved
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Figure 2 | Cellular targets for PfPKG in schizonts. By comparing the impact on the phosphoproteome of the PfPKG inhibitor, Compound 2, in wild-type
3D7 parasites and a mutant parasite strain expressing the Compound 2 insensitive PfPKGT618Q, we identiﬁed 107 phosphorylation sites on 69 parasite
proteins as cellular targets of PfPKG. The proteins were divided into Gene Ontology groups. Those marked with an * are proteins that share an association
with the motor complex, suggesting that they might function as motor-associated proteins.
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histone modiﬁcation, which in mammalian cells is mediated by
Aurora B kinase during mitosis coinciding with chromosome
condensation28. Three Aurora kinase homologues are present in
the P. falciparum genome29 and histone-H3.1 peptides
phosphorylated at S29 and S33 have been identiﬁed in a
previous phosphoproteomic study of Plasmodium falciparum
schizonts12. Moreover, the histone reader Pf14-3-3 has been
shown to speciﬁcally bind histones H3.1 and H3.3
phosphorylated at S29 or dually phosphorylated at S29 and S33
(ref. 30). The functional signiﬁcance of these histone H3
phosphorylations remains uncertain, but their high abundance
suggests a global function in chromatin dynamics rather than
transcriptional regulation of a small subset of genes. Similarly,
histone H2B (PF3D7_1105100) was phosphorylated in a PfPKG-
dependent manner on threonine-14 (T14) (TGTGPDGK). To our
knowledge, this modiﬁcation has not been reported previously
and is not conserved in higher eukaryotes. Interestingly, like H3.1
phosphorylation at S29, H2B phosphorylation at T14 has a
proline in the þ 2 position, a major determinant for 14–3–3
binding31. Intriguingly, our phosphoproteomic analysis also
revealed three PfPKG-dependent phosphorylation events in
a putative regulator of chromosome condensation (PF3D7_
0711500), further linking PfPKG activity to chromatin biology.
Previous studies have also linked cGMP with calcium signalling
in malaria parasites16,18. It is therefore of considerable interest
that the calcium-dependent protein kinase, PfCDPK1, was
identiﬁed here as a cellular target for PfPKG (Fig. 3 and
Supplementary Data set 3). Treatment of wild-type parasites
with Compound 2 resulted in a signiﬁcant reduction in the
phosphorylation of serine 64 (S64) within domain I of
the PfCDPK1 kinase domain (Fig. 3a–d). This change in
phosphorylation was not due to a change in the expression
in PfCDPK1, as non-phosphorylated peptides (for example,
YYFDFNDWK (Fig. 3c)) showed no quantitative change follow-
ing Compound 2 treatment. Importantly, in the PfPKGT618Q
mutant parasite line no change in the phosphorylation of S64 on
Expt 1Expt 2 Expt 3Expt 1 Expt 2 Expt 3
PfCDPK1
Non-phosphorylated (YYFDNDWK)
0.5
0.0
–0.5
–1.0
–1.5
–2.0
Lo
g2
 fo
ld
 c
ha
ng
e
Wild type TQ-mutant
c
Expt 1Expt 2 Expt 3Expt 1 Expt 2 Expt 3
PfCDPK1
Phosphorylated (K/LGpSGAYGEVLLCR)
Wild type
0.5
0.0
–0.5
–1.0
–1.5
–2.0
Lo
g2
 fo
ld
 c
ha
ng
e
TQ-mutant
d
Wild type
PfCDPK1 (LGpSGAYGEVLLCR)
R C
L
L L
G
G G
GE
V
pSGA
E
Y
Y A y-Ion series
b-Ion series
Parent ion-2H-98
(803.43)
R
el
at
ive
 
a
bu
n
da
nc
e
m/z
Expt 2 Expt 3Expt 1
100
50
126.13
128.13
130.14
127.12 129.13 131.14
126 127 128 129 130 131
100
95
90
85
80
75
70
65
60
55
50
40
45
35
30
25
20
15
10
5
0
200 300 400 500 600 700 800 900 1,000 1,100 1,200 1,300
b-ions SEQ y-ions
343.3
400.3
567.3
624.3
695.3
858.4
915.4
1,044.5
1,143.5
1,256.6
1,369.7
1,529.7
1,703.8
L(+2)
G
pS
G
A
Y
G
E
V
L
L
C(+57)
R
1,703.8
1,361.6
1,304.6
1,137.6
1,080.6
1,009.5
846.5
789.4
660.4
561.3
448.2
335.1
175.1
m/z
a
130.4
230.17
175.12
274.12
315.26
348.25
400.27
469.30
487.30
569.36
660.39
695.32
794.43
918.49
946.48
964.49
1,045.56
1,080.55
1,137.57
1,158.64
1,263.61
812.44
803.43
137.67 135.10 130.50
R C
L
L L
G
G
GE
V
pSGAY
EG Y A y-ion series
b-ion series
Parent ion-2H-98
(803.43)
R
el
at
ive
 
a
bu
n
da
nc
e
m/z
100
50
126.13
128.13
130.14
127.13
129.13
131.14
126 127 128 129 130 131
100
95
90
85
80
75
70
65
60
55
50
40
45
35
30
25
20
15
10
5
0
b-ions SEQ y-ions
343.3
400.3
567.3
624.3
695.3
858.4
915.4
1044.5
1,143.5
1,256.6
1,369.7
1,529.7
1,703.8
L(+2)
G
pS
G
A
Y
G
E
V
L
L
C(+57)
R
1,703.8
1,361.6
1,304.6
1,137.6
1,080.6
1,009.5
846.5
789.4
660.4
561.3
448.2
335.1
175.1
200 300 400 500 600 700 800 900 1,000 1,100 1,200 1,300
m/z
TQ-mutanat
PfCDPK1 (LGpSGAYGEVLLCR)
b
128.13
230.17
175.12
248.18
318.12
343.25
400.28
469.30
526.32 596.36
660.39
670.46
794.42 846.45
880.73
946.48
964.49
1,045.56
1,080.54
1,137.57
1,158.64
1,263.62
812.44
803.44
Expt 2 Expt 3Expt 1
Comp 2 – +
75-
50-
TQ-mutant
75-
50-
CDPK1pS64
(Western)
Loading control
100
80
60
40
20
TQ-mutant
%
 B
as
al
 p
S6
4
ph
os
ph
or
yla
tio
n
Control Comp 2
f
Wild type
Comp 2 – +
75-
50-
75-
50-
CDPK1pS64
(Western)
Loading control
100
80
60
40
20
Wild type
%
 B
as
al
 p
S6
4
ph
os
ph
or
yla
tio
n
Control Comp 2
e
***
R
el
at
ive
 a
bu
n
da
nc
e
R
el
at
ive
 a
bu
n
da
nc
e
Figure 3 | PfCDPK1 is a PfPKG cellular target. (a,b) Representative spectra from the global phosphoproteomic data demonstrating that phosphorylation of
serine-64 in PfCDPK1 is downregulated following Compound 2 treatment (2mM, 60min; Comp 2) of wild-type schizonts (a) but not in PfPKGT618Q mutant
parasites (b). The inset on the left is a zoom of each spectrum to show the relative abundance of reporter ions from three experiments (126 and 127 from
Expt. 1, 128 and 129 from Expt. 2, and 130 and 131 from Expt. 3). The inset on the right hand side is the fragmentation table showing the observed b-ions in
orange and y-ions in blue. (c) Box plot representation of the quantitative changes in abundance of a non-phosphorylated PfCDPK1 peptide derived from
wild-type and PfPKGT618Q mutant parasites and (d) of peptides spanning the serine-64 phosphorylation site in PfCDPK1. (e,f) Representative western blots
and quantiﬁcation of n¼ 5 experiments ±s.e.m. showing changes in phosphorylation at serine-64 of PfCDPK1 in wild-type parasites (e) and PfPKGT618Q
parasites (f) using an in-house antibody to phosphoserine-64 on CDPK1 (CDPK1-pS64). Blots were stripped and re-blotted using a structural PfCDPK1
antibody as a loading control. Student’s paired t-test was applied to test statistical signiﬁcance ***Po0.001.
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PfCDPK1 was observed in response to Compound 2 treatment
(Fig. 3a–d). S64 phosphorylation on PfCDPK1 can thus be
considered as a prime example of an on-target action of
Compound 2 on PfPKG.
To further conﬁrm these ﬁndings, parasites expressing a
haemagglutinin (HA)-tagged PfCDPK1, were used to probe the
phosphorylation status of PfCPDK1. Metabolic labelling of the
PfCDPK1-HA-expressing parasites followed by treatment with
vehicle or Compound 2 (2 mM, 60min) demonstrated that the
phosphorylation status of PfCPDK1 was signiﬁcantly decreased
by PfPKG inhibition (Supplementary Fig. 2). Similarly, probing
with an (in-house) phospho-speciﬁc antibody to phosphorylated
S64 on PfCDPK1 (Fig. 3e,f) demonstrated that phosphorylation at
S64 was reduced by Compound 2 treatment in wild-type parasites
(Fig. 3e) but not in PfPKGT618Q mutant parasites (Fig. 3f).
That PfPKG might have a regulatory role in invasion was
indicated by the fact that glideosome-associated protein-40
(PfGAP-40: PF3D7_0515700, PfGAP-45: PF3D7_1222700) and
myosin A ((PfMyoA: PF3D7-1342600); Fig. 2), all of which are
components of a motor protein complex called the glideosome
that is essential for apicomplexan parasite invasion32,33, are
PfPKG cellular targets. Further analysis of the 23 PfPKG cellular
targets with no designated function (labelled ‘uncharacterized
proteins’ in Fig. 2), using GeneDB (http://www.genedb.org/
Homepage) curation, revealed that six of these proteins had
‘Molecular Function’ group assignments (based on an extended
similarity group method34 in the Gene Ontology data) identical to
PfMyoA. The shared Gene Ontology groups were: ‘Motor
Activity’, ‘Actin Binding’ and ‘ATP Binding’. These six proteins
also shared the ‘Myosin Complex Cellular Component’ group
with PfMyoA. These observations may indicate that in addition to
PfGAP-40, PfGAP-45 and PfMyoA, other motor-associated
proteins could be regulated by PfPKG.
We further characterized the phosphorylation of PfMyoA at
serine 19 (S19), as this phosphorylation event had previously been
correlated with calcium35 and PKA-dependent phosphorylation9
and invasion35. Here we conﬁrmed our mass spectrometry data
(Fig. 4a,b) by using an in-house phospho-speciﬁc antibody
to S19 phosphorylation on PfMyoA to monitor the effects of
Compound 2 on the phosphorylation of PfMyoA in wild-type
and PfPKGT618Q mutant parasites and showing that this
phosphorylation event was PfPKG-dependent (Fig. 4c,d).
PfPKG directly mediates phosphorylation of PfCDPK1 in vitro.
The live parasite experiments described above indicate that
PfCDPK1 is phosphorylated in a PfPKG-dependent manner, but
this may not be due to the direct action of PfPKG on PfCDPK1
but rather might be indirect through the action of another kinase
that is itself regulated by PfPKG. To test this we asked if PfPKG
could directly phosphorylate PfCDPK1. First, we established that
puriﬁed recombinant HIS-tagged PfPKG was active and could be
stimulated by cGMP (Fig. 5a). We then generated a catalytically
inactive mutant of PfCDPK1 by mutating the catalytic asparate
191 to asparagine (Supplementary Fig. 3) and used this kinase
dead version (CDPK1-KD) as a substrate for recombinant PfPKG
in an in vitro kinase assay. These experiments revealed that
PfPKG could directly phosphorylate PfCDPK1 in vitro (Fig. 5b).
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Figure 4 | Parasite myosin A (PfMyoA) is a cellular target for PfPKG. (a,b) Box plot display of the quantitative changes in abundance of
(a) a non-phosphorylated PfMyoA peptide derived from wild-type and PfPKGT618Q parasites treated with vehicle or Compound 2 (2mM; Comp 2) and (b) of
a peptide containing the serine-19 phosphorylation of PfMyoA. (c,d) Western blot of parasite lysates prepared from (c) wild-type parasites and (d)
PfPKGT618Q parasites, treated with vehicle or Comp 2 (2 mM). The blots were probed either with a phospho-speciﬁc antibody to phosphorylated serine-19
on PfMyoA (MyoA-pS19) or with an antibody against PfMyoA as a loading control. The western blot data shown are representative of three independent
experiments and the quantiﬁcation of n¼ 3 experiments ±s.e.m. Student’s paired t-test was applied to test statistical signiﬁcance ***Po0.001.
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Western blots using the anti-phospho-S64 PfCDPK1 antibody
determined that S64 was at least one of the sites on PfCDPK1
phosphorylated by PfPKG (Fig. 5c). Mass spectrometry further
conﬁrmed that PfPKG could directly phosphorylate PfCDPK1 at
S64 (Supplementary Fig. 4). Interestingly, these experiments also
determined that PfPKG could phosphorylate PfCDPK1 at
threonine 231 in the activation loop (Supplementary Fig. 4).
The biological signiﬁcance of this second phosphorylation site is,
however, unclear since despite extensive efforts we were not able
to detect this phosphorylation event in vivo.
Serine 64 on PfCDPK1 resides within the glycine-rich loop of
domain I, a region crucial for ATP binding. When residues in this
loop are phosphorylated in certain mammalian kinases, for
example, the cyclin-dependent protein kinase cdk1 (refs 36–38),
this results in abolition of enzymatic activity. We therefore tested
whether PfPKG could regulate the activity of PfCDPK1 through
phosphorylation of S64. We found that puriﬁed recombinant
PfCDPK1 was highly active and able to auto-phosphorylate on
many residues including S64. Substitution of S64 to an alanine
residue (S-A) did not signiﬁcantly change the enzymatic
activity of recombinant PfCDPK1, or the in vitro substrate
speciﬁcity (Supplementary Fig. 5). Furthermore, pre-incubation
of PfCDPK1 with PfPKG resulted in a reduction in PfCDPK1
activity, however, the same reduction was also observed in the
S-A mutant of PfCDPK1 (Supplementary Fig. 5). Hence, it would
appear that PfPKG can decrease the activity of PfCDPK1 in vitro,
but this does not occur via S64 phosphorylation.
It is possible that the reduction of PfCDPK1 activity in the
presence of PfPKG is due to the fact that PfCDPK1 is also
phosphorylated by PfPKG at T231 (Supplementary Fig. 4). We
attempted to test this by mutating T231 to alanine, however, this
PfCDPK1 mutant showed no enzymatic activity. Hence, it would
seem that PfPKG can reduce the activity of PfCDPK1 but
this is not via S64 phosphorylation but may be via T231
phosphorylation.
Phosphorylated PfCDPK1 is associated with apical structures.
We show here that PfCDPK1 was present in infected RBCs at ring
and schizont stage of the erythrocytic asexual cycle as reported
previously39,40 and to a lesser extent in the trophozoite stage
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(Fig. 6a). This is compared with phosphorylation on S64 that
appears to predominantly occur at late schizont stage and be
weakly evident at ring stage (Fig. 6a). The synchronization of the
parasite culture was conﬁrmed by blotting for the schizont-
speciﬁc expression of PfEBA-175, which appears in our cultures
at 40 h post infection consistent with the parasite culture entering
the schizont stage (Fig. 6a).
Immunoﬂuorescence using an anti-HA antibody that detected
PfCDPK1-HA in transgenic parasites revealed the peripheral
(membrane) localization of PfCDPK1 in the nascent merozoites
contained within the late-stage schizonts or free merozoites, in
agreement with previous studies39,40 (Fig. 6b). This localization
was evident in transgenic parasites expressing PfCDPK1-HA, and
stained with anti-HA antibody (Fig. 6b–d), as well as in wild-type
parasites stained with our structural CDPK1 antibody (Fig. 6e,f).
In contrast, S64-phosphorylated PfCDPK1 appeared as discrete
‘punctate spots’ at the periphery of merozoites within late
schizonts (Fig. 6b,e) and within free merozoites (Fig. 6c,d,f).
Although it appears that a small proportion of the
phosphorylated PfCDPK1 signal does not overlap with the total
pool of PfCDPK1, and this may represent a level of nonspeciﬁc
background, immunostaining for CDPK1-pS64 was substantially
reduced following 1 h treatment with Compound 2 (Fig. 6b),
conﬁrming the speciﬁcity of the pS64 phospho-speciﬁc antibody.
Furthermore, the phosphorylated form of PfCDPK1 in
merozoites contained within late-stage schizonts or free mer-
ozoites was localized close to the micronemes (labelled with anti-
EBA-175 antibodies41) and rhoptries (labelled with anti-
PfTRAMP antibodies42). It is important to note that the
phosphorylated PfCDPK1 does not appear within the apical
organelle structures themselves (correlation coefﬁcient for
EBA175 and CDPK1-pS64 in merozoites¼ 0.301 and for
TRAMP and CDPK1-pS64¼ 0.414) but rather is located close
to these structures. Thus, we conclude that the phosphorylated
form of PfCDPK1 is largely located at the apical pole of the
parasite (Fig. 7a,b). (Z-stacks for the 3D-reconstructed ﬁgures
presented in Fig. 6e,f as well as in Fig. 7a,b are shown in
Supplementary Movies 1–6.)
Phosphorylated PfCDPK1 contributes to complex formation.
The possibility that phosphorylation of PfCDPK1 might regulate
protein–protein interactions was tested by size exclusion
chromatography where PfCDPK1 was observed to exist as both a
B60-kDa monomer and a high-molecular-weight complex
running between 250 and 400 kDa (Fig. 8a). Treatment of para-
sites with Compound 2 appeared to have a subtle but signiﬁcant
effect on complex formation as indicated by a reduction in the
proportion of PfCDPK1 in the high-molecular-weight complex
and an increase in the proportion of monomeric PfCDPK1
(Fig. 8b). This reduction in response to Compound 2 was not
evident in PfPKGT618Q mutant parasites (Fig. 8c) indicating that
S64 phosphorylation mediated by PfPKG is involved in main-
taining a proportion of PfCDPK1 within a high-molecular-weight
complex, although the precise nature of the complex has still to be
deﬁned.
It was decided to probe the possibility that PfPKG could be
part of the high-molecular-weight PfCDPK1 complex. However,
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probing the gel ﬁltration fractions for PfPKG revealed that the
kinase was only present in the low-molecular-weight fractions
consistent with PfPKG monomer and therefore was not
part of any high–molecular-weight complex with PfCDPK1
(Supplementary Fig. 6).
PfPKG activity is essential for merozoites RBC invasion. We
determine here that a number of PfPKG cellular targets, not least
PfCDPK1 and components of the glideosome complex, are cru-
cially involved in parasite invasion. These data support the notion
that PfPKG regulates invasion. To test this, we conducted an
invasion assay that monitored the invasion of free merozoites
(separated from schizonts by 1.2 mm pore ﬁltration) into RBCs
(Fig. 9). In this experiment, Compound 2 completely inhibited
invasion of wild-type merozoites but had only a small effect on
invasion of PfPKGT618Q mutants merozoites (Fig. 9a,b). These
data are consistent with a role for PfPKG in invasion and
supports the notion that the phosphorylation of key proteins
involved in the invasion process such as PfMyoA and PfCDPK1
might contribute to the mechanism of action of PfPKG.
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Fraction 7 8 9 10 11 12 13 14 15 16 17 18
Monomer
Monomer
High Mwt
complex
High Mwt
complex
MonomerHigh Mwt
complex
CDPK1-HA100
100
80
60
40
20
0
100
80
60
40
20
0
70
50
37
Pe
rc
e
n
ta
ge
 o
f t
ot
al
Pe
rc
e
n
ta
ge
 o
f t
ot
al
Wild type Control
Compound 2
Control
Compound 2
P<0.05
P<0.05
PfPKGT618Q
Figure 8 | PfCDPK1 exists as a high-molecular-weight (Mwt) complex
that is regulated by PfPKG. (a) A parasite lysate was prepared from
parasites expressing a HA-tagged PfCDPK1. The lysate was fractionated
over a Superdex 200 gel ﬁltration column and the fractions probed by
western blot with an anti-HA antibody. Shown is a representative of three
independent experiments. (b) Quantiﬁcation of the relative proportion of
CDPK1-HA staining that appears in the high-Mwt complex and in the
monomeric form—from parasites treated with vehicle and from parasites
treated with Compound 2. (c) The experiment shown in b was repeated
using the PfPKGT618Q mutant parasites. In this instance, the fractions from
the Superdex column were probed with the structural CDPK1 antibody to
detect the high-Mwt complex and the monomeric form of PfCDPK1. The
results shown are from three experiments ±s.e.m. Student’s paired t-test
was applied to test statistical signiﬁcance.
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Discussion
By employing a chemical genetic approach in conjunction with
quantitative global phosphoproteomics, we describe here 107
phosphorylation events in the human malaria parasite that are
dependent on PfPKG activity. In this way, we not only reveal the
cellular targets (either direct or indirect) of cGMP-signalling in
malaria, but we also provide a map of the physiological processes
that are likely regulated by PfPKG (see, Fig. 2). In addition, by
deﬁning cellular effectors of PfPKG we have gained insight into
cGMP/PfPKG phospho-signalling pathways and feed-back loops,
and particularly the relationship between PfPKG signalling and
calcium signalling in malaria parasites.
This relationship was particularly evident in parasite egress and
invasion. Previous studies had demonstrated that intracellular
calcium levels rise sharply before parasite egress43, a process that
is blocked by chelating intracellular calcium with BAPTA-
AM15,43. The rise in calcium has been proposed to initiate the
release of exoneme proteins, in particular, the subtilisin-like
serine protease PfSUB1 (ref. 15) and microneme proteins (for
example, PfAMA1 and PfEBA175)44, in a process that is essential
for egress and invasion15,44,45. That this also involves PfPKG is
evident by our previous report that increasing parasite
intracellular concentrations of cGMP, by inhibition of parasite
cGMP-phosphodiesterase with zaprinast, resulted in parasite
egress in a PfPKG-dependent manner15. Furthermore,
microneme discharge and parasite egress can be prevented by
the treatment of parasites with Compound 2 (ref. 15) and by
inhibition of PfCDPK1 (refs 46,47). It would seem, therefore, that
there is a close relationship between changes in intracellular
calcium, calcium signalling through PfCDPK1 and the activity
of PfPKG, in the regulation of exoneme and microneme
discharge associated with egress and invasion. Our studies
would indicate that one important component of this
relationship is the ability of PfPKG to phosphorylate a sub-
population of PfCDPK1 at the apical pole of the parasite. These
data, together with fact that PfPKG-dependent phosphorylation
of PfCDPK1 impacts on the nature of the PfCDPK1-complex,
present the possibility PfPKG exerts regulation of microneme
release and parasite invasion by the phosphorylation of PfCDPK1
at the apical pole (Fig. 10).
Such a mechanism may well run in conjunction with other
processes orchestrated by PfPKG. In particular, recent studies in
both P. berghei and P. falciparum have determined that PfPKG
can mediate changes in intracellular calcium via the regulation of
phosphoinositide biosynthesis18—the lipid precursors of inositol
trisphosphate (IP3) that is proposed to act in Plasmodium in a
similar way to mammalian cells, to mobilize intracellular
calcium44,48. It is therefore possible that increased PfPKG
activity before egress can initiate not only the PfCDPK1
phosphorylation and complex formation but also propagate an
increase in intracellular calcium that activates calcium-dependent
phosphorylation, which subsequently contributes to microneme
discharge and parasite egress. Thus, our study, in conjunction
with others, highlights the complex relationship between cGMP/
PfPKG and calcium/PfCDPK1 signalling in the regulation of
parasite egress and provides direct evidence for the involvement
of phospho-signalling cascades in this key process.
The possibility that PfPKG can impact further on parasite
egress is evident by our intriguing ﬁnding that schizont egress
antigen-1 (PfSEA-1, PF3D7_1021800) is phosphorylated in a
PfPKG-dependent manner. Antibodies to PfSEA-1 have recently
been reported in Tanzanian children resistant to severe malaria49,
where a block of PfSEA-1 has been proposed to inhibit merozoite
egress49. We identiﬁed here 11 sites of phosphorylation on
PfSEA-1, of which serine-280 in the N-terminal region was
phosphorylated in a PfPKG-dependent manner—providing an
additional potential mechanism for PfPKG-mediated regulation
of parasite egress.
That PfPKG-mediated signalling has an impact on invasion is
evidenced here by the PfPKG-mediated phosphorylation of
PfMyoA, PfGAP40 and PfGAP45, crucial components of the
glideosome complex40. In particular, PfGAP45 was found to be a
substrate for PfCDPK1, which appears to phosphorylate PfGAP45
at serine-89 and serine-103 (ref. 50). Interestingly, we identiﬁed
both sites as phosphorylated in our in vivo study, but they were
not signiﬁcantly changed by treating parasites with Compound 2
and therefore were not PfPKG-dependent. Surprisingly, we
identiﬁed two additional sites serine-149 and serine-156 that
were PfPKG-dependent, indicating that calcium/PfCDPK1
signalling and cGMP/PfPKG signalling in this instance
converge in the regulation of PfGAP45 by acting at
independent sites. The relationship between cGMP and calcium
signalling in the regulation of PfGAP45 may extend further. It has
been reported that PfGAP45 can be phosphorylated by PfPKB,
which, unlike the mammalian orthologue that acts downstream
of phosphoinositides, is regulated in a calcium/calmodulin-
dependent manner51. Of further interest was the phosphory-
lation of PfMyoA at S19, a site identiﬁed as phosphorylated
in vivo in all the previous global phosphoproteomic studies9–12
and suggested to be a PfPKA site based on (i) the close match to
the consensus PKA sequence and (ii) the observation that a
peptide corresponding to this site was phosphorylated by
mammalian PKA9. Our studies would indicate that this site is
phosphorylated in a PfPKG-dependent manner, although it is not
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Figure 9 | Parasite red blood cell invasion is dependent on PfPKG
activity. (a) Invasion of wild-type free merozoites into red blood cells was
monitored in the absence or presence of Compound 2 (2 mM; Comp 2) by
the determination of the number of infected red blood cells 24 h post
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survival of the parasites post invasion. (b) The invasion of PfPKGT618Q
merozoites into red blood cells was monitored. The results are the mean of
3–5 experiments ±s.e.m. Student’s paired t-test was applied to test
statistical signiﬁcance. ***Po0.001, *Po0.05.
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possible to determine at this stage if this is a direct action of
PfPKG or whether PfPKG upregulates the activity of another
kinase, such as PfPKA, and that this kinase then phosphorylates
PfMyoA. This might be possible as our studies demonstrate that
one of the adenylyl cyclases (PfACb) and a phosphodiesterase
(PDEb) were phosphorylated in a PfPKG-dependent manner,
which may provide a mechanism through which PfPKG could
impact on cAMP/PfPKA signalling.
Thus, our results suggest that PfPKG regulates parasite in-
vasion, a notion that was upheld in our study when Compound 2
was shown to inhibit invasion of free merozoites into RBCs.
Importantly, the effect of Compound 2 was clearly mediated by
PfPKG, as its effect on parasite invasion was signiﬁcantly reduced
in the PfPKGT618Q mutant parasite strain. Hence, we show here
that PfPKG activity is essential for parasite invasion and that this
correlates with the identiﬁcation of a number of key proteins
involved in parasite invasion that are phosphorylated in a
PfPKG-dependent manner (Fig. 10).
In conclusion, our study is among the ﬁrst to use quantitative
phospho-proteomics in combination with chemical genetics to
dissect phospho-signalling in malaria and extends signiﬁcantly
our understanding of the role played by phosphorylation from
the previously published global phospho-proteomic studies that
simply identiﬁed parasite phospho-proteins9–12,52. By employing
the techniques described here, we establish that malaria protein
kinases can reside within phospho-signalling cascades and,
similar to mammalian systems, a certain number of these
parasite kinases form signalling hubs able to interact with a
large number of downstream systems. It would appear that
PfPKG represents one of these essential signalling hubs
where signalling through cyclic nucleotides, calcium and
phosphoinositides16,18 appear to converge. In this context it
would seem that targeting PfPKG would have a wide impact on
essential parasite signalling. That this is the case is supported by
the fact that PfPKG is an essential kinase11,14 and that inhibition
of this kinase is shown here to prevent merozoite invasion in
addition to other key life cycle events such as schizogony14,
egress15,16, gametogenesis17 and ookinete motility18,19. These
widespread effects of inhibition of PfPKG activity supports our
notion that PfPKG acts as an essential signalling hub and as such
would represent an excellent drug target in the treatment of
malaria and blocking its transmission to mosquitoes.
Methods
Parasite culture and synchronization of parasites. P. falciparum blood stage
3D7 (wild type)-, PKGT618Q- and CDPK1-HA-parasites were cultured using a
standard method53. Parasites were grown in complete RPMI 1640 medium
(RPMI 1640 medium with 2mM L-glutamine, 25mM HEPES, 2 g l 1 NaHCO3,
27.2mg l 1 hypoxanthine and 0.5% Albumax II, pH7.4) using Oþ human RBC at
37 C in an incubator with 5% CO2, 5% O2 and 90% N2. PKGT618Q and CDPK1-
HA parasites were grown with the selection drug WR99210 (10 nM). Sorbitol
treatment was used to synchronize the parasites54: parasites were treated with 5%
sorbitol for 20min at room temperature to lyse trophozoite and schizont stage
parasites. Dead parasites were removed by two washes with incomplete RPMI
medium (RPMI 1640 medium with 2mM L-glutamine, 25mM HEPES, pH 7.4).
Following sorbitol treatment parasites were transferred to complete RPMI 1640
medium.
For the time-course experiments, parasites were synchronized by two rounds of
sorbitol treatment—ﬁrst treatment when the parasites culture was at late ring/
trophozoite stage and second when the parasite culture contained schizonts and
ring stage parasites. After second sorbitol treatment, parasite cultures were
collected for the ﬁrst time point (8 h) and further samples were collected at every
8 h as indicated. Please note that we calculated that each time point has variation of
±2 h. Parasites from infected cells for the ﬁrst three time points (8, 16 and 24 h)
were collected by two saponin treatments (0.1%) for 10min. Subsequent time
points (32, 40 and 48 h) were collected by magnet-assisted cell sorter (MACS)
puriﬁcation followed by saponin treatment (0.1%) for 10min. The parasite
fractions were then washed at least three times with PBS before being prepared for
gel electrophoresis.
Cloning of CDPK1 and site-directed mutagenesis. Bacterial expression of
full-length PfCDPK1 was achieved by ampliﬁcation of the Pfcdpk1-coding sequence
from a 3D7 schizonts cDNA preparation using CDPK1-FL-His-Fwd and
CDPK1-FL-His-Rev primers (see primer list) and cloning into pLEICS05 plasmid
(PROTEX, University of Leicester, UK), which produces a PfCDPK1 protein with a
6-HIS tag at the C-terminus. For expression of PfCDPK1 as an N-terminal
GST-tagged protein, the Pfcdpk1 gene was ampliﬁed using CDPK1-FL-GST-Fwd
and CDPK1-FL-GST-Rev primers and cloned in pGEX-2T plasmid (GE
Healthcare). Site-directed mutagenesis (QuikChange II kit, Agilent Technologies),
using primers CDPK1-D191N-Fwd and CDPK1-D191N-Rev, was performed to
convert aspartate to asparagine at residue-191 of PfCDPK1 to generate the kinase
dead variant, CDPK1-KD. Similarly, serine-64 on PfCDPK1 was changed to
alanine using the primers CDPK1-S64A-Fwd and CDPK1-S64A-Rev primers.
Generation and screening of parasites expressing CDPK1-HA. A plasmid
containing a recodonized version of base pairs 436–1,572 of the pfcdpk1 ORF
between XmaI (50) and AvrII (30) cloning sites was synthesized by GeneArt. The
synthetic sequence also contained a novel EcoRI site at position 436–441, produced
through introduction of synonymous mutations. A region of homology to facilitate
integration of the plasmid via single crossover homologous recombination was
ampliﬁed from P. falciparum 3D7 genomic DNA: 194 bp upstream of the ATG to
base pair 435 of the open reading frame using primers 1 and 2. This fragment
was cloned via XmaI and EcoRI sites into the GeneArt vector containing the
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Figure 10 | Schematic representation of the role of cGMP/PfPKG signalling in egress/invasion. The present study has identiﬁed a number of
cellular targets for PfPKG, which appear to map to the reported roles for cGMP and calcium signalling in egress and invasion. We describe here the
PfPKG-dependent phosphorylation of a subpopulation of PfCDPK1 localized at the apical pole, which together with other calcium-dependent kinases,
most notably PfCDPK5, represents an interplay between calcium and cGMP/PfPKG signalling necessary to mediate egress. Interestingly, this may also
involve phosphorylation of additional proteins involved in egress, such as the recently described PfSEA1, which we demonstrate here to be a target (either
direct or indirect) for PfPKG. Furthermore, the identiﬁcation of a number of proteins involved in parasite invasion, particularly those associated with the
actomyosin motor complex, provides a mechanistic explanation for the essential role played by PfPKG in invasion that is described in our study.
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recodonized gene. Finally, the combined 2.5 kb fragment containing the native and
recodonized cdpk1 sequences was cloned between XmaI and AvrII sites of the
pHH4-HA plasmid (gift from Dr E. Knuepfer, NIMR), which adds a triple HA tag
at the 30 end followed by a stop codon and the PbDT 30 UTR and hDHFR drug
selection cassette.
P. falciparum 3D7 parasites were transfected with 100mg pHH4-CDPK1-HA
plasmid using standard methods55,56. They were maintained under drug pressure
(25 nM WR99210) until resistant parasites emerged, cycled on/off drug and cloned
by limiting dilution. Clones were screened by PCR using primers 4 and 5 to detect
integration at the cdpk1 locus, and primers 4 and 6 which would amplify from the
unmodiﬁed locus (Supplementary Fig. 7). Positive clones were conﬁrmed by
western blot using anti-CDPK1 (described elsewhere40 and anti-HA (3F10; Roche)
antibodies.
Immunoﬂuorescence assays. Smears were prepared from PfCDPK1-HA
transgenic parasite culture containing schizonts after treatment with vehicle or
Compound 2 (2 mM, 60min) and 3D7 parasite culture containing schizonts and
merozoites. Smears were dried for 30min and washed with Tris-buffered saline
(TBS) for 10min. Smears were ﬁxed with 4% paraformaldehyde (PFA) for 10min,
washed with TBS and permeabilized with 0.1% Triton X-100. Slides were blocked
overnight at 4 C using 4% BSA. Smears were probed with a rabbit antisera raised
against phosphoserine-64 on PfCDPK1 (CDPK1-pS64), a monoclonal rat anti-HA
antibody (clone 3F10) and a rat antibody against recombinant PfCDPK1 (CDPK1)
at 1:100 dilution in TBS containing 1% BSA. Mouse sera against PfEBA175 and
PfTRAMP were also used at 1:100 dilution in TBS containing 1% BSA as markers
for apical organelles. Alexa-Fluor 546-conjugated anti-rat IgG goat antibodies
(1:1,000 dilution) and Alexa-Fluor 488-conjugated anti-rabbit IgG goat antibodies
(1:1,000 dilution) were used as secondary antibodies with PfCDPK1-HA transgenic
parasite. Alexa-Fluor 594-conjugated anti-rat IgG goat antibodies (1:500 dilution),
Alexa-Fluor 594-conjugated anti-mouse IgG goat antibodies (1:500 dilution) and
Alexa-Fluor 488-conjugated anti-rabbit IgG goat antibodies (1:200 dilution)
were used as secondary antibodies with 3D7 parasites. Slides were mounted with
40 ,6-diamidino-2-phenylindole dihydrochloride (DAPI) and anti-fade mounting
medium (Molecular Probes) and analysed using either a Nikon A1-R confocal
microscope (for 3D7 parasites) or a Zeiss Axio Observer Z1 confocal microscope
(for PfCDPK1-HA parasites).
Images (labelled as rendered images in the manuscript) were processed using
Imaris version 6.4.2 or 7.0.0 (Bitplane Scientiﬁc), which enables visualization,
segmentation and interpretation of three-dimensional (3D) microscopy data sets.
For clarity of display, deconvoluted z stacks were reconstructed in 3D, with
interpolation. To see the extent of co-localization between PfCDPK1-pS64 (green)
and PfCDPK1 (red) a separate co-localization channel (shown in yellow;
PfCDPK1þPfCDPK1-pS64) was built. The red channel (for PfCDPK1) was made
transparent to allow visualization of DAPI and staining for PfCDPK1 (green) or
overlap of PfCDPK1-pS64 and PfCDPK1.
Bacterial protein expression. Full-length PfCDPK1 as a 6-HIS- or GST-tagged
protein was expressed in the BL21-CodonPlus(DE3)-RIPL strain (Agilent Tech-
nologies) of E. coli. Cells were treated with 100mM IPTG when the optical density
of the cell culture at 600 nm reached 0.6, and gene expression was induced for 4 h at
22 C.
To purify 6-HIS-tagged CDPK1, cells were lysed in buffer (20mM Tris-HCl,
150mM NaCl, 1mM DTT, Protease Inhibitor Cocktail (Roche) pH7.4) by
sonication. After sonication lysates were centrifuged at 20,000g for 30min and
supernatants were collected. Supernatants were loaded on pre-equilibrated Ni-NTA
Superﬂow resin (QIAGEN). Loaded resin was washed with buffer (20mM
Tris-HCl, 150mM NaCl and 1mM dithiothreitol (DTT), pH 7.4) and proteins
eluted with the same buffer containing 350mM Imidazole, at pH 8.0. Eluted
proteins were dialysed against 20mM Tris-HCl, 150mM NaCl and 1mM DTT,
pH7.4.
To purify GST-tagged PfCDPK1, cells were lysed in buffer (PBS containing
1mM DTT, 1mM EDTA and Protease Inhibitor Cocktail (Roche), pH7.4) by
sonication. After sonication, the lysate was centrifuged at 20,000g for 30min and
the supernatant collected. Supernatant was loaded on pre-equilibrated glutathione
Sepharose-4B resin (GE Healthcare). Loaded resin was washed with PBS
containing 1mM DTT and 1mM EDTA, pH7.4, and protein was eluted with the
same buffer containing 20mM reduced glutathione. Eluted proteins were dialysed
in dialysis buffer and stored at  80 C.
Antibody generation. PfCDPK1 ‘structural’ antibody (recognizing both
phosphorylated and non-phosphorylated PfCDPK1) was raised by immunizing rats
with recombinant CDPK1-6HIS protein by Eurogentec, using a standard 87-day
immunization protocol. Brieﬂy two rats were immunized with 30 mg of protein on
day 0 followed by boosts on days 14, 28 and 56. The ﬁnal bleed was collected
on day 87. IgG from the serum was puriﬁed on Protein G-Sepharose fast ﬂow
(GE Healthcare) and used for the study.
Phospho-speciﬁc Serine-64 PfCDPK1 antibody was raised by immunizing
rabbits with phospho-peptide CKVRKLGS(PO3H2)GAYGE. Rabbit immunizations
and puriﬁcation of phospho-speciﬁc antibody was done by Eurogentec following
their 87-day immunization protocol. Brieﬂy two rabbits were immunized with
peptide coupled to KLH carrier on day 0 followed by three boosts on day 21, 49
and 77, and the ﬁnal bleed was collected on day 87. ELISA against peptide and
carrier was used to select the ﬁnal serum sample with the best titre for the
puriﬁcation of phospho-speciﬁc antibody. Speciﬁc antibody was puriﬁed by two
rounds of puriﬁcation: ﬁrst, the serum was passed through a column with
conjugated phospho-peptide, then the bound antibodies were eluted and passed
through a second column with conjugated non-phosphorylated peptide
(CKVRKLGSGAYGE). The ﬂow-through that contained the phospho-speciﬁc
antibody, as conﬁrmed by ELISA, was collected.
The phosopho-speciﬁc antibody to PfMyoA phospho-serine 19 was produced
by Genosphere Biotechnologies. Rabbits were immunized with the peptide
‘N’-RRV[pS]NVEAFDKC conjugated to KLH. The resulting antisera was afﬁnity-
puriﬁed on the phosphopeptide followed by afﬁnity chromatography on the
non-phosphopeptide. The ﬂow-through from the second puriﬁcation contains a
majority of anti-phospho-peptide antibodies and was used in western blots at a
dilution of 1:1,000.
Labelling of PfCDPK1-HA parasites and immunoprecipitation. Late schizont-
stage PfCDPK1-HA parasites were harvested on a MACS column (Miltenyi Biotec)
in Krebs buffer (10mM HEPES, containing 118.4mM NaCl, 4.69mM KCl,
4.17mM NaHCO3, 1.18mM MgSO4, 1.29mM CaCl2 and 11.7mM glucose,
pH7.4). Puriﬁed schizonts were pre-incubated with vehicle (0.2% dimethyl
sulphoxide) or 2 mM Compound 2 for 10min at 37 C, then 32P-orthophosphate
(7.4 MBq) was added and the incubation continued at 37 C for 30min. The
schizonts were washed twice with Krebs buffer and resuspended in 0.1% (w/v)
saponin in PBS for 10min on ice. Following saponin treatment, the cells were
washed twice with PBS and then lysed in lysis buffer-A (20mM Tris, 1mM EDTA,
20mM b-Glycerol Phosphate, 1% (v/v) Nonidet P-40 and protease and
phosphatase inhibitor cocktail (Roche), pH7.4). The lysate was centrifuged
at 20,000g for 5min and the supernatant used for immunoprecipitation.
To immunoprecipitate CDPK1-HA, the supernatant was incubated with 20 ml HA-
afﬁnity matrix (immobilized anti-HA high-afﬁnity rat monoclonal antibody, clone
3F10 (Roche)) at 4 C for 1 h with constant mixing. The matrix was then washed
ﬁve times with lysis buffer-A without NP-40, and an equal volume of Laemmli
buffer was added to the matrix. Proteins were separated by SDS–polyacrylamide gel
electrophoresis (PAGE) on a 10% polyacrylamide gel, and stained with Coomassie
blue before the gel was dried and exposed to X-ray ﬁlm.
In vitro kinase assays for PfPKG. CDPK1-HIS (1 mg) or CDPK1-S64A-HIS (1mg)
proteins were incubated with or without Histone Type IIA (2 mg), Myelin Basic
Protein (2mg; MBP) and a-Casein (2 mg) in kinase buffer (10mM HEPES, 10mM
MgCl2 and 1mM DTT, pH7.4) containing 1mM CaCl2, 50mM ATP and 0.0185
MBq 32P-ATP for 30min at 30 C.
To examine the phosphorylation of PfCDPK1-KD by PfPKG in an in vitro
kinase assay, recombinant HIS-tagged PfPKG protein (1 mg) was incubated with or
without CDPK1-KD protein (1mg) in kinase buffer containing 10 mM cGMP,
50 mM ATP and 0.0185 MBq P32-ATP for 30min at 37 C. CDPK1-KD (1 mg) was
incubated in a similar condition without cGMP.
Following incubation, reactions were stopped by adding an equal volume of
2 Laemmli buffer and proteins were separated by SDS–PAGE on a 10% gel
and stained with Coomassie blue. Dried gels were exposed to X-ray ﬁlm and
autoradiograms collected.
To examine phosphorylation of PfCDPK1 at serine-64, PfPKG-HIS tagged
(50 ng) was incubated with or without CDPK1-KD (50 ng) and CDPK1-S64A-KD
(50 ng) in kinase buffer containing 10 mM cGMP and 50mM ATP for 30min at
37 C. CDPK1-KD (50 ng) and CDPK1-S64A-KD (50 ng) were also incubated in a
similar condition without cGMP. Following incubation, the reaction was stopped
with Laemmli buffer and samples were used for SDS–PAGE and western blotting.
PfCDPK1 protein kinase activity assay. Recombinant His-tagged WT or S64A
variant PfCDPK1 were assayed for protein kinase activity using MBP as a substrate.
In the ﬁrst part of the assay, recombinant PfCDPK1-6His was incubated in the
presence or absence of PfPKG-His plus 10mM cGMP in the reaction mix
containing 50 mM ATP and 32P-ATP in kinase buffer (20mM HEPES, 1mM
MgCl2, 20mM b-glycerol phosphate, pH 7.5) for 30min at 37 C. Following the
incubation, PfPKG-dependent phosphorylation of PfCDPK1 was stopped by
adding Compound 2 to a ﬁnal concentration of 2 mM and further incubated for
10min at room temperature. The same amount of Compound 2 was added to
control samples not containing PfPKG to exclude any inhibitory effect of the
compound on PfCDPK1 in the second part of the assay. Protein kinase activity of
PfCDPK1 was assayed by transferring 75% of the ﬁrst reaction mix into a clean
Eppendorf tube containing 2 mg MBP, 1mM CaCl2, 50 mM ATP and 32P-ATP in
the kinase buffer at 30 C, and incubation for different times. The reaction was
stopped by transferring samples into ice and spotting 20 ml aliquots onto P-81
phospho-cellulose paper (Whatman). The P-81 paper was washed with 0.5%
phosphoric acid to remove nonspeciﬁc background and incorporated radioactivity
was measured.
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Western blotting. Twenty micrograms of parasite lysates or 50 ng of recombinant
proteins were resolved by SDS–PAGE on a 10% gel. After separation, proteins were
transferred to a nitrocellulose membrane. Membranes were blocked with 5%
skimmed milk solution in Tris buffer-saline (pH 7.4) containing 1% Tween-20.
Then membranes were probed with either structural CDPK1 antibody (1:1,000
dilution), pS64-phospho-speciﬁc CDPK1 antibody (1:1,000) or monoclonal HA
antibody (1:1,000). HRP-tagged rat or rabbit secondary antibody was used at
1:2,000 dilution. Blots were developed by enhanced chemiluminescence reagent
and ﬂuorograms were collected.
EBA-175 antibody (1:1000) used was an in house antibody generated in the
Tobin laboratory against recombinant EBA-175 region III-IV.
Invasion assay with live merozoites. Merozoites used in the invasion assay were
puriﬁed as described earlier57. Brieﬂy, 3D7 or PfPKGT618Q parasites were
synchronized by two sorbitol treatments in the same cycle. Schizonts from 120ml
parasite culture with 4% haematocrit and 2–4% parasitemia were puriﬁed on a
MACS column. Puriﬁed schizonts were treated with 10 mM N-(trans-
Epoxysuccinyl)-L-leucine 4-guanidinobutylamide (E-64) in complete RPMI
medium for 4 h and then schizonts were passed through an Acrodisc 1.2 mm pore
membrane syringe ﬁlter (Pall Corporation) to collect free merozoites. Free
merozoites were added to complete RPMI 1640 medium containing RBC and
either 2 mM Compound 2 or the vehicle (dimethyl sulphoxide), then parasites were
allowed to invade RBC and grow for 24 h under standard culturing conditions. In
one well, Compound 2 was added 1 h post invasion and parasites were allowed to
develop to the 24-h time point. Smears were made, stained with Giemsa stain and
the percentage of infected RBC was counted by microscopy. The experiment was
done three times with duplicate wells for each condition.
Gel-ﬁltration on Superdex 200. PfCDPK1-HA or PfPKGT618Q parasites were
cultured in complete RPMI medium until late schizont stage and harvested on a
MACS column. Puriﬁed schizonts were resuspended in the same medium, split
into two equal aliquots and incubated in the presence of either 10 mM E-64 and
2 mM Compound 2 or 10mM E-64 and vehicle alone, for 3 h at 37 C. Following the
treatment, samples were incubated on ice with 0.1% saponin in PBS supplemented
with protease and phosphatase inhibitors (Roche), the cells were harvested by
centrifugation and cell pellets washed twice with TEG buffer (50mM Tris-HCl,
0.5mM EDTA, 5% b-Glycerol phosphate, pH 7.4,supplemented with protease and
phosphatase inhibitors). The parasite pellets were lysed in TEG buffer (plus
protease and phosphatase inhibitors) in the presence of 0.1% NP-40 for 10min on
ice followed by 4 10 s sonication. Samples were cleared by centrifugation at
20,000g for 3min and the supernatant fraction was collected and centrifuged
again at 20,000g for 3min to remove any further insoluble material. Protein
concentration in the soluble lysate was in the range of 2.5–3.0mg per ml in a ﬁnal
volume of B0.5ml.
This sample (300–350 ml) was then loaded onto a Superdex 200 column
(GE Healthcare, 10 300mm) equilibrated with running buffer (50mM Tris-HCl,
0.15M NaCl, 20mM b-glycerol phosphate, pH7.4) and run at a ﬂow rate of 50 ml
per min at 4 C on an AKTA Puriﬁer (Amersham Pharmacia Biotech). Fractions
(1ml) were collected and analysed by western blot—probed with antibodies against
the HA-tag or the structural CDPK-antibody.
Preparation of P. falciparum proteins for mass spectrometry. Late-stage
schizonts (segmented) were harvested on a MACS CS column (Miltenyi Biotec) in
complete RPMI 1640 medium. The parasites were split into two equal aliquots and
incubated in the presence or absence of Compound 2 (2 mM) for 1 h at 37 C in
complete RPMI 1640 medium. Following incubation, the parasites were pelleted by
centrifugation and resuspended in 0.1% (w/v) saponin in PBS supplemented with
protease and phosphatase inhibitors (Roche) and incubated 10min at 4 C. The
saponin-treated parasites were collected by centrifugation and then lysed with TEG
buffer (50mM Tris-HCl, 0.5mM EDTA, 5% b-glycerol phosphate, 1% NP-40, pH
7.4) containing protease and phosphatase inhibitors (Roche) on ice for 10min.
Samples were centrifuged at 20,000g for 3min, and the supernatant collected. The
pellet was resuspended in TEG buffer without NP-40 and sonicated 3 15 s on ice
and then centrifuged at 20,000g for 3min. The two supernatant fractions were then
pooled. Protein concentration in the ﬁnal lysates was in the range of 2–4mgml 1
in a total volume of 0.45–0.5ml depending on the initial number of cells.
Tryptic digestion and TMT labelling of parasite proteins. Parasite lysates were
diluted in TE buffer (10mM Tris, 5mM EDTA, 20mM b-glycerol phosphate, pH
7.4) to give a ﬁnal measure of 0.6–0.7mg protein in 1ml total volume. This was
then incubated at 37 C for 30min in the presence 10mM DTT and 0.1% SDS.
Iodoacetamide (1M solution) was then added to a ﬁnal concentration of 100mM
and incubation was continued for another 1 h at room temperature in the dark.
Protein was precipitated on ice by addition of 100% trichloroacetic acid (at a ratio
of 1:4) to the samples and harvested by centrifugation for 3min at 2,000g followed
by two gentle washes without disturbing the pellets. The protein pellets were
sonicated in 50mM TEAB buffer (triethylammonium bicarbonate, pH 8.5) and
digested with trypsin (Promega) at a ratio of 1:20 (w/w) trypsin to protein content,
overnight at 37 C on a rotating platform.
For tandem mass tag labelling (TMT labelling), completely digested samples
were concentrated to about 250–300 ml in a Speedvac centrifuge and labelled with
6-plex TMT reagents (Thermo scientiﬁc) following the manufacturer’s instructions.
TMT-labelled samples were pooled and concentrated to a volume of 750 ml in a
Speedvac centrifuge, and then mixed with 250ml of 100% acetonitrile (ACN) and
diluted with 10mM TEAB, pH 8.0 to a ﬁnal volume of 3ml. The sample was
loaded onto a Resource Q anion-exchange column (1ml bed volume, GE
Healthcare) equilibrated with 10mM TEAB, pH 8.0. Peptides were eluted by a
linear gradient of 0–1M NaCl in 10mM TEAB, pH 7.0, collecting 1ml fractions.
The fractions associated with the ﬂow-through (fractions 2–4) were combined and
wash fractions (fractions 5–7) were combined. The ﬂow-through and wash
fractions were then concentrated on a speedvac to 1ml total volume for each. The
combined ﬂow-through and wash fractions together with each of the gradient
eluate fractions (fractions 10–16) were prepared for immobilized metal afﬁnity
chromatography (IMAC) and titanium dioxide (TiO2) enrichment of
phosphopeptides.
IMAC enrichment of phosphopeptides for mass spectrometry. Fractions from
the anion exchange column step were adjusted to pH 2.5–3.0 by adding 50%
triﬂuoroacetic acid (TFA). PHOS-Select beads (Sigma) were equilibrated with
loading/wash buffer (0.25M acetic acid, 30% acetonitrile) and 50 ml of 50% slurry
was added to each fraction, followed by rotating at room temperature for 1–2 h.
After incubation with IMAC beads, the samples were transferred onto Mobicol
‘Classic’ spin columns (2B Scientiﬁc Ltd), centrifuged for 30 s at 1,000g, and the
ﬂow-through (ﬁltrate) collected and used for further enrichment on TiO2 beads as
described below. The IMAC beads were washed twice with 200ml of loading/wash
solution, once with 200 ml of HPLC grade water and eluted twice with 100 ml of
eluting solution composed of 22 ml ammonia solution (Fisher Chemical, 35%
stock), 300 ml acetonitrile to a total volume of 1ml with water. Eluates were con-
centrated to a small volume (15–20 ml) on a Speedvac centrifuge and submitted for
mass spectrometry analysis.
TiO2 enrichment of phosphopeptides for mass spectrometry. The ﬁltrates from
the PHOS-Select-treated samples were used for further phosphopeptide enrich-
ment essentially as described in ref. 58. Brieﬂy, each sample was treated with 5mg
of TiO2 beads (GL Sciences Inc) in the presence of 30mg 2,5-dihydroxybenzoic
acid for 1–2 h on a rotating platform at room temperature. Following treatment,
the samples were ﬁltered on Mobicol ‘Classic’ spin columns, then the beads were
washed once with 200ml of 30% ACN, 0.5% TFA and once with the same volume
of 80% ACN, 0.1% TFA by centrifugation for 30 s at 1,000g. Phosphopeptides
bound to the TiO2 beads were eluted twice with 100 ml of 15% ammonia solution.
Eluates were concentrated to a small volume (15–20 ml) and submitted for mass
spectrometry analysis.
Mass spectrometry and data processing. LC-MS/MS was carried out using an
RSLCnano HPLC system (Dionex) and an LTQ-Orbitrap-Velos mass spectrometer
(Thermo Scientiﬁc). Samples were loaded at high-ﬂow rate onto a reverse-phase
trap column (0.3mm i.d. 1mm), containing 5 mm C18 300Å Acclaim PepMap
medium (Dionex) maintained at a temperature of 37 C. The loading buffer was
0.1% formic acid/0.05% TFA/2% ACN. Peptides were eluted from the column at a
ﬂow rate of 0.3 ml min 1 and passed through a reverse-phase PicoFrit capillary
column (75 mm i.d. 400mm) containing Symmetry C18 100Å medium (Waters)
that was packed in-house using a high-pressure device (Proxeon Biosystems).
Peptides were eluted over a period of 4 h, with the output of the column sprayed
directly into the nanospray ion source of the LTQ-Orbitrap-Velos mass spectrometer.
The LTQ-Orbitrap-Velos mass spectrometer was set to acquire a 1 microscan
Fourier transform mass spectrometer (FTMS) scan event at 60,000 resolution over
the m/z range 300–2,000Da in positive ion mode. The maximum injection time for
MS was 500ms and the AGC target setting was 1e6. Accurate calibration of the
FTMS scan was achieved using a background ion lock mass for C6H10O14S3
(401.922718Da). Subsequently, up to ten data-dependent higher-energy collision
dissociation (HCD) MS/MS were triggered from the FTMS scan. The isolation
width was 2.0Da, with normalized collision energy of 42.5. Dynamic exclusion was
enabled. The maximum injection time for MS/MS was 250ms and the AGC target
setting was 5e4.
The raw data ﬁle obtained from each LC-MS/MS acquisition was processed
using Proteome Discoverer (version 1.4.0.288, Thermo Scientiﬁc), searching each
ﬁle in turn using Mascot59 (version 2.2.04, Matrix Science Ltd.) against the
UniProtKB-Swissprot database. The peptide tolerance was set to 10 p.p.m. and
the MS/MS tolerance was set to 0.02Da. Fixed modiﬁcations were set as
carboxyamidomethyl (C) and variable modiﬁcations set as oxidation (M) and
phosphorylation (S/T/Y). A decoy database search was performed.
The output from Proteome Discoverer was further processed using Scaffold
Qþ S60 (version 4.0.5, Proteome Software). Upon import, the data were searched
using X!Tandem61 (The Global Proteome Machine Organization).
PeptideProphet62 and ProteinProphet63 (Institute for Systems Biology) probability
thresholds of 95% were calculated from the decoy searches and Scaffold was used to
calculate an improved 95% peptide and protein probability threshold based on the
data from the two different search algorithms.
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Phosphoproteomic data analysis. Plotting the log2 mean fold change of the total
peptides from each of the three experiments with wild-type parasites revealed a
normal distribution of differences in peptide abundance resulting from the treat-
ment of parasites with Compound 2 (Supplementary Fig. 8). The phospho-peptides
that appeared in the lower quartile of the distribution curve in all three wild-type
parasite experiments were considered to be downregulated by the treatment with
Compound 2.
Next, we examined whether those phosphopeptides considered as
downregulated by Compound 2 treatment of wild-type parasites were also
downregulated in the Compound 2-treated PfPKGT618Q parasite (note: for a
phospho-peptide to be considered downregulated, it had to fall within the lower
quartile of the distribution curve in all three wild-type experiments and to be
detected in all three of the PfPKGT618Q parasite experiments). This was done using
a mixed regression test to determine whether there was a signiﬁcant difference
between the log2 mean fold change of the selected phosphopeptides in the wild-
type and PfPKGT618Q parasites. Those phosphopeptides that were downregulated
in both the wild-type parasite and in the PfPKGT618Q mutant parasite were
considered to result from off-target effects of Compound 2. In contrast, those
phosphopeptides that were downregulated in the wild-type parasite samples but
were signiﬁcantly less downregulated in the PfPKGT618Q parasite samples were
considered as resulting from on-target effects of Compound 2 and therefore
constituted cellular targets of PfPKG.
Primers. The primers used in this study are listed in Supplementary Table 1.
Other Data analysis. Where indicated Student’s paired t-test was used.
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